Both the IDH1 wild type and mutant showed significant difference with respect to use of TMZ chemotherapy and in fact displayed better OS across all histological types of glioma patients (log-rank p < 0.05: Supplementary Figure 2A). This evidence concerns the gene IDH1 and central nervous system cancer.